Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics

This study investigates the anticancer potential of existing anti-viral drugs using a comprehensive suite of computational methods. A dataset of 76 antiviral drugs was prepared and optimized for analysis. Through the application of network pharmacology, gene ontology, and Kyoto Encyclopedia of Genes...

Full description

Saved in:
Bibliographic Details
Main Authors: Uma Maheshwari Mugundan, Praveen Sekar, Rajanandh Muhasaparur Ganesan
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Chemical Physics Impact
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667022424003566
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849334625293303808
author Uma Maheshwari Mugundan
Praveen Sekar
Rajanandh Muhasaparur Ganesan
author_facet Uma Maheshwari Mugundan
Praveen Sekar
Rajanandh Muhasaparur Ganesan
author_sort Uma Maheshwari Mugundan
collection DOAJ
description This study investigates the anticancer potential of existing anti-viral drugs using a comprehensive suite of computational methods. A dataset of 76 antiviral drugs was prepared and optimized for analysis. Through the application of network pharmacology, gene ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, this study identified Human Epidermal Growth Factor Receptor 2 (HER2) and Poly [ADP ribose] polymerase 1(PARP-1) as key targets involved in the molecular pathways associated with breast cancer. Protein sequence alignment further revealed conserved and semi-conserved amino acid regions, including residues such as Arginine (ARG), Aspartic acid (ASP), and Phenylalanine (PHE), offering valuable insights into the structural characteristics of the target proteins. Molecular docking studies were performed to evaluate drug-receptor interactions, leading to the selection of promising candidates: Fostemsavir, Efavirenz, Doravirine, and Didanosine for HER2, and Efavirenz, Lopinavir, Fostemsavir, and Elvitegravir for PARP-1. The binding affinities observed were -7.92 Kcal/mol for HER2 and -8.08 Kcal/mol for PARP-1 for Efavirenz, and -8.17 Kcal/mol for HER2 and -7.91 Kcal/mol for PARP-1 for Fostemsavir. Subsequent molecular dynamics simulations, conducted over 200 ns, assessed the stability of these drug-protein complexes. Binding free energy was calculated using Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) methods, reinforcing the stability and efficacy of the selected compounds followed by entropy calculation using Normal mode analysis done for Efavirenz complexes. Results of this study demonstrated that Efavirenz exhibits strong binding and notable potential as HER2 and PARP-1 inhibitors. Efavirenz demonstrated effectiveness against both targets, emphasizing its potential and showcasing drug repurposing as a promising strategy in cancer therapy development.
format Article
id doaj-art-8f55c5ca7a734edeafd9ada27b742df2
institution Kabale University
issn 2667-0224
language English
publishDate 2025-06-01
publisher Elsevier
record_format Article
series Chemical Physics Impact
spelling doaj-art-8f55c5ca7a734edeafd9ada27b742df22025-08-20T03:45:31ZengElsevierChemical Physics Impact2667-02242025-06-011010081210.1016/j.chphi.2024.100812Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanicsUma Maheshwari Mugundan0Praveen Sekar1Rajanandh Muhasaparur Ganesan2Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, 603203, Tamilnadu, IndiaDepartment of Pharmaceutical Chemistry, Swamy Vivekanandha College of Pharmacy, Tiruchengode, 637205, Tamilnadu, IndiaDepartment of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, 603203, Tamilnadu, India; Corresponding author.This study investigates the anticancer potential of existing anti-viral drugs using a comprehensive suite of computational methods. A dataset of 76 antiviral drugs was prepared and optimized for analysis. Through the application of network pharmacology, gene ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, this study identified Human Epidermal Growth Factor Receptor 2 (HER2) and Poly [ADP ribose] polymerase 1(PARP-1) as key targets involved in the molecular pathways associated with breast cancer. Protein sequence alignment further revealed conserved and semi-conserved amino acid regions, including residues such as Arginine (ARG), Aspartic acid (ASP), and Phenylalanine (PHE), offering valuable insights into the structural characteristics of the target proteins. Molecular docking studies were performed to evaluate drug-receptor interactions, leading to the selection of promising candidates: Fostemsavir, Efavirenz, Doravirine, and Didanosine for HER2, and Efavirenz, Lopinavir, Fostemsavir, and Elvitegravir for PARP-1. The binding affinities observed were -7.92 Kcal/mol for HER2 and -8.08 Kcal/mol for PARP-1 for Efavirenz, and -8.17 Kcal/mol for HER2 and -7.91 Kcal/mol for PARP-1 for Fostemsavir. Subsequent molecular dynamics simulations, conducted over 200 ns, assessed the stability of these drug-protein complexes. Binding free energy was calculated using Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) methods, reinforcing the stability and efficacy of the selected compounds followed by entropy calculation using Normal mode analysis done for Efavirenz complexes. Results of this study demonstrated that Efavirenz exhibits strong binding and notable potential as HER2 and PARP-1 inhibitors. Efavirenz demonstrated effectiveness against both targets, emphasizing its potential and showcasing drug repurposing as a promising strategy in cancer therapy development.http://www.sciencedirect.com/science/article/pii/S2667022424003566Breast cancerDrug repurposingAnti-cancerNetwork pharmacologyMolecular simulations
spellingShingle Uma Maheshwari Mugundan
Praveen Sekar
Rajanandh Muhasaparur Ganesan
Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
Chemical Physics Impact
Breast cancer
Drug repurposing
Anti-cancer
Network pharmacology
Molecular simulations
title Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
title_full Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
title_fullStr Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
title_full_unstemmed Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
title_short Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
title_sort repurposing antiviral drugs targeting the parp 1 and her2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics
topic Breast cancer
Drug repurposing
Anti-cancer
Network pharmacology
Molecular simulations
url http://www.sciencedirect.com/science/article/pii/S2667022424003566
work_keys_str_mv AT umamaheshwarimugundan repurposingantiviraldrugstargetingtheparp1andher2pathwayswithmultifacetedimpactsthroughintegratednetworkanalysisandmolecularmechanics
AT praveensekar repurposingantiviraldrugstargetingtheparp1andher2pathwayswithmultifacetedimpactsthroughintegratednetworkanalysisandmolecularmechanics
AT rajanandhmuhasaparurganesan repurposingantiviraldrugstargetingtheparp1andher2pathwayswithmultifacetedimpactsthroughintegratednetworkanalysisandmolecularmechanics